Peterson Yuri K, Luttrell Louis M
Department of Drug Discovery and Biomedical Sciences, College of Pharmacy (Y.K.P.), and Departments of Medicine and Biochemistry and Molecular Biology (L.M.L.), Medical University of South Carolina, Charleston, South Carolina; and Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina (L.M.L.).
Department of Drug Discovery and Biomedical Sciences, College of Pharmacy (Y.K.P.), and Departments of Medicine and Biochemistry and Molecular Biology (L.M.L.), Medical University of South Carolina, Charleston, South Carolina; and Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina (L.M.L.)
Pharmacol Rev. 2017 Jul;69(3):256-297. doi: 10.1124/pr.116.013367.
The visual/-arrestins, a small family of proteins originally described for their role in the desensitization and intracellular trafficking of G protein-coupled receptors (GPCRs), have emerged as key regulators of multiple signaling pathways. Evolutionarily related to a larger group of regulatory scaffolds that share a common arrestin fold, the visual/-arrestins acquired the capacity to detect and bind activated GPCRs on the plasma membrane, which enables them to control GPCR desensitization, internalization, and intracellular trafficking. By acting as scaffolds that bind key pathway intermediates, visual/-arrestins both influence the tonic level of pathway activity in cells and, in some cases, serve as ligand-regulated scaffolds for GPCR-mediated signaling. Growing evidence supports the physiologic and pathophysiologic roles of arrestins and underscores their potential as therapeutic targets. Circumventing arrestin-dependent GPCR desensitization may alleviate the problem of tachyphylaxis to drugs that target GPCRs, and find application in the management of chronic pain, asthma, and psychiatric illness. As signaling scaffolds, arrestins are also central regulators of pathways controlling cell growth, migration, and survival, suggesting that manipulating their scaffolding functions may be beneficial in inflammatory diseases, fibrosis, and cancer. In this review we examine the structure-function relationships that enable arrestins to perform their diverse roles, addressing arrestin structure at the molecular level, the relationship between arrestin conformation and function, and sites of interaction between arrestins, GPCRs, and nonreceptor-binding partners. We conclude with a discussion of arrestins as therapeutic targets and the settings in which manipulating arrestin function might be of clinical benefit.
视觉/β-抑制蛋白是一个小家族的蛋白质,最初因其在G蛋白偶联受体(GPCRs)脱敏和细胞内运输中的作用而被描述,现已成为多种信号通路的关键调节因子。视觉/β-抑制蛋白与一大组具有共同抑制蛋白折叠的调节支架在进化上相关,它们获得了在质膜上检测和结合活化GPCRs的能力,这使它们能够控制GPCRs的脱敏、内化和细胞内运输。通过作为结合关键信号通路中间体的支架,视觉/β-抑制蛋白既影响细胞中信号通路活性的基础水平,在某些情况下,还作为GPCR介导信号的配体调节支架。越来越多的证据支持抑制蛋白的生理和病理生理作用,并强调了它们作为治疗靶点的潜力。规避依赖抑制蛋白介导的GPCR脱敏可能会缓解对靶向GPCR药物的快速耐受问题,并可应用于慢性疼痛、哮喘和精神疾病的治疗。作为信号支架,抑制蛋白也是控制细胞生长、迁移和存活的信号通路的核心调节因子,这表明操纵它们的支架功能可能对炎症性疾病、纤维化和癌症有益。在这篇综述中,我们研究了使抑制蛋白能够发挥其多种作用的结构-功能关系,讨论了抑制蛋白在分子水平上的结构、抑制蛋白构象与功能之间的关系,以及抑制蛋白、GPCRs和非受体结合伙伴之间的相互作用位点。我们最后讨论了抑制蛋白作为治疗靶点以及操纵抑制蛋白功能可能具有临床益处的情况。